Last reviewed · How we verify
NCT07241182
Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy
NA trial testing Antrodia cinnamomea supplement in Lung Cancer (Diagnosis) in 40 participants. Currently enrolling.
31 March 2027
Quick facts
| Lead sponsor | Tri-Service General Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 40 |
| Start date | 24 November 2025 |
| Primary completion | 31 March 2027 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Antrodia cinnamomea supplement
- Turmeric-Probiotic Group
Conditions studied
- Lung Cancer (Diagnosis) — all drugs for Lung Cancer (Diagnosis) →
Sponsor
Tri-Service General Hospital
Who can join
Adults 18 to 99, any sex, with Lung Cancer (Diagnosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized trial will test whether Antrodia cinnamomea supplement improves quality of life in lung cancer patients receiving platinum-based chemotherapy. Participants at Tri-Service General Hospital will be randomized to receive either Antrodia cinnamomea capsules or placebo for 3 months, with follow-up to 6 months (24 weeks). Primary outcomes include nausea/vomiting scores, sleep quality, quality of life, and cancer symptoms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07241182
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer (Diagnosis)
Currently open trials in the same condition.
- NCT07168993 — Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Di · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07231159 — Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots · recruiting
Other Tri-Service General Hospital trials
Trials by the same sponsor.
- NCT07515495 — Effectiveness of Intensive Tutoring vs. Flexible Self-Learning on Digital Health Literacy and Self-Efficacy for "My Heal · NA · recruiting
- NCT07589322 — Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs · NA · recruiting
- NCT07327385 — To Investigate the Change of Brain and Autonomic Function From Different Protocols of Repeated Transcranial Magnetic Sti · NA · not yet recruiting
- NCT07355023 — AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Targe · NA · recruiting
- NCT06932614 — Comparing the Efficacy of Lyophilized Self Growth Factor Versus PRP Injection for Knee OA · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07241182 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tri-Service General Hospital
- Last refreshed: 8 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07241182.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing